Eye (London, England) · 2026
Standalone versus combined preserflo MicroShunt surgery: A two-year controlled cohort study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
García-Bardera Javier, Garcia-Feijoo Julián, García-Bermúdez Mireia, Ponce-de-León-Miguel Álvaro, Ginés-Gallego Cristina, Méndez-Hernández Carmen, García-Sáenz Sofía, Fernández-Vidal Ana, Morales-Fernández Laura, Martínez-de-la-Casa Jose María
Аннотация
OBJECTIVES: To compare efficacy, safety, and surgical success of standalone Preserflo MicroShunt (PMS) implantation versus PMS combined with phacoemulsification in open-angle glaucoma (OAG).
METHODS: A retrospective cohort study included consecutive OAG patients who underwent standalone or combined PMS surgery with 0.04% mitomycin C at a tertiary centre. Primary outcomes were intraocular pressure (IOP), glaucoma medications, and surgical success at 2 years. Success was defined as ≥20% IOP reduction with IOP <18 mmHg (criterion 1) or ≥30% reduction with IOP <18 mmHg (criterion 2).
RESULTS: A total of 173 eyes (113 standalone, 60 combined) were analysed. Mean IOP decreased from 22.1 ± 5.8 mmHg to 12.5 ± 3.1 mmHg ( - 39.4%) in the standalone group and from 20.6 ± 6.7 mmHg to 14.2 ± 4.0 mmHg ( - 33.0%) in the combined group (p = 0.023; 95% CI -3.16 to -0.25), with similar medication use in both groups. Success rates were 76.1% versus 61.7% for criterion 1 (p = 0.084) and 70.0% versus 41.7% for criterion 2 (p = 0.001). Kaplan-Meier analysis showed higher cumulative success in standalone surgery (criterion 1: HR 1.77, p = 0.044; criterion 2: HR 2.40, p = 0.0003). Complications occurred in 38.2% of eyes (36.3% standalone, 41.7% combined), with only 6.4% requiring surgical intervention.
CONCLUSION: Both standalone and combined PMS implantation achieved significant IOP and medication reductions with acceptable safety. However, standalone PMS appears to offer superior mid-term IOP control and higher surgical success, supporting its use in advanced glaucoma cases requiring maximal pressure reduction.
METHODS: A retrospective cohort study included consecutive OAG patients who underwent standalone or combined PMS surgery with 0.04% mitomycin C at a tertiary centre. Primary outcomes were intraocular pressure (IOP), glaucoma medications, and surgical success at 2 years. Success was defined as ≥20% IOP reduction with IOP <18 mmHg (criterion 1) or ≥30% reduction with IOP <18 mmHg (criterion 2).
RESULTS: A total of 173 eyes (113 standalone, 60 combined) were analysed. Mean IOP decreased from 22.1 ± 5.8 mmHg to 12.5 ± 3.1 mmHg ( - 39.4%) in the standalone group and from 20.6 ± 6.7 mmHg to 14.2 ± 4.0 mmHg ( - 33.0%) in the combined group (p = 0.023; 95% CI -3.16 to -0.25), with similar medication use in both groups. Success rates were 76.1% versus 61.7% for criterion 1 (p = 0.084) and 70.0% versus 41.7% for criterion 2 (p = 0.001). Kaplan-Meier analysis showed higher cumulative success in standalone surgery (criterion 1: HR 1.77, p = 0.044; criterion 2: HR 2.40, p = 0.0003). Complications occurred in 38.2% of eyes (36.3% standalone, 41.7% combined), with only 6.4% requiring surgical intervention.
CONCLUSION: Both standalone and combined PMS implantation achieved significant IOP and medication reductions with acceptable safety. However, standalone PMS appears to offer superior mid-term IOP control and higher surgical success, supporting its use in advanced glaucoma cases requiring maximal pressure reduction.